Lactobacillus sakei to Treat Sinusitis

Evidence Review created on 09/25/2026 using AI4L + evidence-mcp / Grok 4

Also known as: Latilactobacillus sakei, L. sakei, Lactobacillus sakei subsp. sakei, Lactobacillus sakei subsp. carnosus, Latilactobacillus sakei subsp. sakei, Latilactobacillus sakei subsp. carnosus, Lactobacillus sake, Lactobacillus bavaricus

Motivation

Lactobacillus sakei is a lactic-acid bacterium long used to ferment foods such as kimchi, sake, and cured meat. It also appears, usually in small amounts, in the noses of people without long-running sinus inflammation, and it is scarce in many people who live with that illness. A mouse experiment in which the organism limited damage from another sinus bacterium is why a refrigerated powder is now applied in the nose.

Interest grew once microbiome comparisons framed chronic sinusitis less as one invading bacterium and more as a thinned community. Self-experimenters began applying kimchi juice in the nostrils, and a commercial powder of one kimchi strain followed. Oral trials on skin, body fat, and knee pain do not answer the sinus question. No completed trial has tested whether nasal application changes sinus symptoms, and an irrigation trial is still in progress.

This review examines what Lactobacillus sakei is, how it is thought to act on the sinus lining, what human and animal evidence shows for sinus symptoms and for effects outside the nose, and what is known about harm, product quality, practical use, and how a change would be recognized.

Benefits - Risks - Protocol - Conclusion

Clinician commentary and primary papers that discuss this species, or nasal probiotics built around it, in enough depth to orient the topic.

Fewer than five sources are listed. Writing that discusses this species for sinus disease in any depth is scarce outside the primary papers and one clinician essay. No directly relevant item was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Life Extension, or Lifespan.io. A FoundMyFitness note names the species only in a plastic-particle experiment. A Life Extension kimchi recipe cites an oral body-fat trial in its references and does not discuss sinus use. Systematic reviews were left for the next section.

Grokipedia

  • Latilactobacillus sakei

    A species overview of taxonomy, fermented-food habitats, and probiotic uses. Useful orientation; it is not a sinusitis evidence review.

Examine

No primary Examine.com article on Lactobacillus sakei was found. The supplement URL returns a page-not-found result. Search hits are research-feed study summaries, not a dedicated page for the organism.

ConsumerLab

No dedicated ConsumerLab article on Lactobacillus sakei was found. The search returned general probiotic reviews and unrelated answers. The site notes that a term may appear only inside a members-only report.

Systematic Reviews

Two meta-analyses include this species, one on knee pain and one on infant atopic dermatitis (a long-running allergic skin rash); none covers nasal use or harm from this species alone.

Mechanism of Action

Lactobacillus sakei, reclassified as Latilactobacillus sakei, is a lactic-acid bacterium, not a small-molecule drug. It has no plasma half-life and is not cleared by CYP3A4 (a common drug-metabolizing enzyme). A nasal effect depends on live cells surviving clearance long enough to change the lining.

People with chronic rhinosinusitis (CRS, long-running inflammation of the nose and sinus lining) had a less diverse community, fewer lactic-acid bacteria, and more Corynebacterium tuberculostearicum. In mice whose sinus bacteria had been thinned, that organism increased mucus-producing cells, and L. sakei limited the injury (Abreu et al.). Groups were about three mice and have not been repeated (De Boeck et al.). The same university group later patented this kind of bacterium for sinusitis, so the claim and an intellectual-property interest sit together.

The organism makes lactic acid, which lowers pH, and many strains make bacteriocins (small antibacterial proteins) active against gram-positive bacteria such as Staphylococcus aureus. That is competition, not an immune drug. Nose isolate L. sakei AMBR8 did not reseal polyp lining cells (a polyp is a growth on the lining), while Lacticaseibacillus casei AMBR2 did, via Toll-like receptor 2 (TLR2, a sensor for bacterial fragments) (Martens et al.). Strain may matter more than the species name. Healthy noses carry more lactobacilli, including this group, than CRS noses, but presence is not proof that a powder rebuilds the community (De Boeck et al.).

Historical Context & Evolution

Lactobacillus sakei fermented sake, kimchi, and cured meat long before any sinus use. It was valued because it grows in the cold and crowds out spoilage bacteria. That history is about food, not the nose.

In 2012 a University of California, San Francisco group compared sinus bacteria in people with and without chronic rhinosinusitis, then tested candidates in mice (Abreu et al.). Human samples showed a thinner community and more Corynebacterium tuberculostearicum. In mice, one strain limited the damage that organism caused after other bacteria had been cleared. Those findings, not a later dismissal, made this species a candidate rather than a proven therapy. The group later patented lactic-acid bacteria for sinusitis. The data remain; the claim was produced by a party with an intellectual-property interest.

From about 2013, people with long-running symptoms, described on a patient site and then by Chris Kresser, applied live kimchi juice in the nostrils and reported personal improvement. A refrigerated powder of kimchi strain proBio65, sold as Lanto Sinus by Lanto Health and marketed for sinus support, followed. In 2020 the species moved to the genus Latilactobacillus; labels still use the old name. A controlled irrigation trial of that powder opened in 2025 and has no results. The mouse result stands, with tiny groups. A later lab study found another strain of the same species did not reseal a leaky lining (Martens et al.). Neither result has been retired.

Expected Benefits

High 🟩 🟩 🟩

Lower Atopic Dermatitis (a long-running allergic skin rash) Scores ⭕️ Not Central to Treat Sinusitis

Oral Lactobacillus sakei lowered children’s skin-inflammation scores, which does not bear on sinusitis. Strain KCTC 10755BP improved SCORing Atopic Dermatitis (SCORAD, a skin-severity score) by 13.1 points versus 5.2 with placebo over 12 weeks (Woo et al.). Live and heat-killed proBio65 also lowered scores where placebo did not (Rather et al.). This is immune calming after oral use, not nasal use in adults with sinus disease.

Magnitude: Mean skin-severity score improved by 13.1 points (31%) with strain KCTC 10755BP versus 5.2 points (13%) with placebo over 12 weeks.

Medium 🟩 🟩

Lower Knee Pain and Function Scores ⭕️ Not Central to Treat Sinusitis

Orally administered strain LB-P12 improved knee pain and function more than placebo in one 12-week trial of 100 adults, which does not bear on sinusitis (Shine et al.). WOMAC (a knee pain and function score) fell about 3.7 points with the organism and rose about 2.0 with placebo. Interleukin-1β (IL-1β, an inflammatory signal) also fell, and no adverse events were reported. LISCure Biosciences authors developed the strain, and the gap was smaller than the trial was built to detect.

Magnitude: WOMAC total score changed by about −3.7 points with LB-P12 versus about +2.0 points with placebo at 12 weeks (intent-to-treat, counting everyone in the assigned group).

Lower Dry-Eye Scores ⭕️ Not Central to Treat Sinusitis

An eye-drop lysate of Lactobacillus sakei (killed cells, not a live dose) improved dry-eye scores more than placebo in one trial of 40 adults, which does not bear on sinusitis (Heydari et al.). Oral capsules of the same organism did not. The Ocular Surface Disease Index (OSDI, a dry-eye symptom score), tear stability, and tear volume all improved with the drops.

Magnitude: Symptom, tear-stability, and tear-volume scores improved with the lysate drops versus placebo. The abstract reports no point change.

Better Cheek Elasticity ⭕️ Not Central to Treat Sinusitis

Heat-killed Lactobacillus sakei KABP-065 improved cheek elasticity more than placebo over 8 weeks in healthy women aged 30 to 49 (Sawashita et al.). Moisture rose in both groups. Kaneka authors developed this heat-killed product (a postbiotic: killed microbes). This is oral use, not a sinus outcome.

Magnitude: Cheek skin-recovery rose by about 6.6 percentage points (from about 59% to 65%) with the postbiotic versus about 3.4 percentage points (from about 61% to 65%) with placebo at 8 weeks. The larger change versus placebo was clear at 5 weeks and only a trend at 8 weeks.

Low 🟩

Smaller Body-Fat Mass ⚠️ Conflicted ⭕️ Not Central to Treat Sinusitis

Two oral trials disagree on total fat mass, which does not bear on sinusitis. CJLS03, from CJ CheilJedang authors, left fat mass 0.8 kg below placebo (Lim et al.). OK67, from Dongwha authors, did not, though visceral fat fell (Oh et al.). A general fat-mass effect is not established.

Magnitude: With strain CJLS03, fat mass was 0.8 kg lower than placebo at 12 weeks (a 0.2 kg loss versus a 0.6 kg gain).

Speculative 🟨

Less Pathogen-Driven Sinus Inflammation

One mouse strain limited mucus overgrowth from a sinus pathobiont (Abreu et al.). No human symptom trial exists, and one nose isolate failed to reseal lining (Martens et al.).

Benefit-Modifying Factors

  • Baseline community: People whose sinus samples lack lactic-acid bacteria are the group the microbiome studies flag. No routine test selects them before a course.

  • Baseline biomarkers: No blood marker is known to enlarge a benefit. Skin trials used a symptom-score cutoff, not a lab value, and that cutoff does not select who might respond in the nose.

  • Prior sinus surgery: Opened cavities are the population in the ongoing irrigation trial. Whether an unoperated nose responds the same way is unknown.

  • Recent or current antibiotics: A recent antibacterial course thins the community this organism would join, and an ongoing course can kill it.

  • Age: Skin-score trials enrolled children and adolescents only. Older adults more often have chronic sinusitis; a sinus benefit at older ages is unmeasured.

  • Sex: No sex difference in response is reported for skin, knee, fat, or sinus outcomes.

  • Genetic variants: No gene variant has been shown to enlarge or shrink a benefit from this species.

  • Strain and viability: A culture-collection strain, kimchi powder, and kimchi juice are not interchangeable. Heat-killed cells helped skin scores when administered orally; they are untested in the nose.

  • Polyps versus no polyps: The barrier assay that this species failed was done on polyp lining. Results may not apply to sinusitis without polyps.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no replicated human trial has documented a clinical adverse event from Lactobacillus sakei.

Medium 🟥 🟥

No risk reaches Medium: oral trials report mild events at rates similar to placebo, which is not a consistent harm signal, and no observational series has defined a specific adverse outcome.

Low 🟥

Gastrointestinal Upset With Oral Use

A drug monograph lists flatulence and gastrointestinal discomfort as common oral effects, which does not bear on nasal use. The kimchi-strain fat trial counted flatulence and gastrointestinal discomfort at rates like placebo (Lim et al.). The counts do not show an excess over placebo.

Magnitude: Flatulence was 36.2% with CJLS03 versus 35.4% with placebo, and gastrointestinal discomfort was 31.9% versus 27.1%, over 12 weeks.

Invasive Infection in Vulnerable Hosts

Other lactobacilli rarely infect the blood or a heart valve in very ill people or those with abnormal valves. A case report ties this species to septic arthritis (a joint infection) (Cabrera Romero et al.). No bloodstream case names it. Beyond that report, the concern is extrapolated.

Magnitude: Not quantified in available studies. One case report gives no rate, and the oral trials did not record this outcome.

Speculative 🟨

Nasal Irritation With Topical Use

Stinging, sneezing, or dryness is described by people using powders or kimchi juice in the nose. No controlled count of that irritation exists, so the basis is anecdotal.

Risk-Modifying Factors

  • Immune compromise: A theoretical translocation risk (live cells crossing into the blood), inferred from other lactobacilli, rises with neutropenia (too few bacteria-fighting white cells), chemotherapy, or a central venous line.

  • Baseline labs: No blood test is known to enlarge harm from this species. A neutrophil count below 500 per microliter is a reason to avoid live cells, not a dose change.

  • Heart valves: Prosthetic valves and prior valve infection are the setting in which a lactobacillus in the blood becomes a valve infection.

  • Route: Nasal use puts live cells on lining that may be raw after surgery. Oral use is what the human safety trials actually tested.

  • Age: Preterm infants are a high-risk group for probiotic bloodstream infection from other species. Frail older adults share the immune concern. Healthy adults in oral trials did not show excess harm.

  • Sex: No sex difference in adverse events is reported.

  • Dose and viability: A larger live dose raises exposure. Heat-killed cells cannot invade, and they also cannot do what a live nasal dose is hoped to do.

Key Interactions & Contraindications

  • Systemic antibiotics (ampicillin, amoxicillin, penicillin): Caution. These drugs kill gram-positive bacteria, including this species, so a live dose during treatment is unlikely to persist. Separating doses does not fix an ongoing course. The result is loss of the organism, not drug toxicity.

  • Topical nasal antibacterials and antiseptics (mupirocin, povidone-iodine rinses): Caution. They inactivate bacteria on the lining. Same-day use leaves an inactive dose.

  • Over-the-counter decongestant sprays (oxymetazoline): No direct inactivation is documented. Prolonged decongestant use irritates the lining on its own. Monitor comfort if both are used.

  • Other probiotic supplements: Caution. No specific interaction is documented. Several live products at once have no sinus trial, and no dose change is established.

  • Supplements sometimes used for sinus symptoms (lactoferrin, saline irrigation): Caution. No additive effect has been shown in people. In the ongoing trial, saline is the comparator, not a proven partner.

Populations who should avoid Lactobacillus sakei:

  • Severe immune suppression, including absolute neutrophil count below 500 per microliter, active chemotherapy, or the months after a blood stem-cell transplant. Thresholds mark a high theoretical risk of bloodstream infection.
  • A prosthetic heart valve, prior infective endocarditis (a heart-valve infection), or a recent valve operation. Live bacteria in the blood are dangerous on abnormal valves.
  • Preterm infants. Probiotic bloodstream infection is documented for other species in this group, and this species is unstudied there.
  • Known allergy to the organism or to the powder’s other ingredients (microcrystalline cellulose, dextrose in the commercial product).

Risk Mitigation Strategies

  • Skip live cells when immunity is severely low: Avoids theoretical bloodstream infection when neutrophils are below 500 per microliter, during chemotherapy, or early after a stem-cell transplant.

  • Skip live cells with an abnormal valve: Avoids seeding a prosthetic valve or a valve already damaged by infection.

  • Sterile water only: Bottled, distilled, or boiled-and-cooled water keeps other organisms out of the rinse, which limits the chance of an invasive infection.

  • Stop if the nose stings: Burning, sneezing, or dryness is a reason to stop. That limits nasal irritation from a topical dose.

  • Short course only: Stopping once symptoms settle limits how long live cells are applied, which limits nasal irritation and theoretical bloodstream infection.

  • Watch for fever or spreading pain: Fever, new facial redness, or severe headache is a reason to stop. Those signs fit invasive infection, not ordinary irritation.

  • Ease oral flatulence: Flatulence or gastrointestinal discomfort is the common oral effect. Administering the dose with a meal, or stopping it, limits that discomfort.

Therapeutic Protocol

  • Commercial powder, once daily: Lanto Sinus (L. sakei proBio65; Lanto Health) is named in the ongoing trial. The label uses ¼ teaspoon (1 g) in sterile water, applied in each nostril, the rest administered orally, once daily during symptoms.

  • Colony count: The 15 g bottle is labeled 17 billion colony-forming units (CFU, a count of live cells) at manufacture, about 1 billion CFU per gram. That is a supplement claim, not a tested dose.

  • Kimchi-juice swab: Live, unpasteurized kimchi juice, discussed by Kresser from patient self-experiment, is applied inside the nostrils. Strain and count are unknown and vary by jar.

  • Irrigation under study: One trial mixes proBio65 into 240 mL distilled or boiled water twice daily for 14 days after sinus surgery. Saline is only the comparator. No results yet.

  • Time of day: No circadian preference is established. Nasal use does not depend on meals. After an oral rinse, the label says not to eat or drink for several minutes.

  • Single versus split dose: Consumer labels describe one application a day. The irrigation trial uses two a day. No comparison of those schedules exists.

  • Half-life: No plasma half-life applies. The nose clears most material within minutes. Persistence of this species in people is unmeasured. A different nasal lactobacillus lasted hours to about two weeks.

  • Genetic variants: No variant, including drug-metabolism genes, has been shown to change dose or response.

  • Sex: No sex-specific dose or efficacy figure exists for sinus use or for the oral trials.

  • Age: Oral skin trials enrolled children and adolescents, not as a nasal dose. Older adults clear the nose more slowly and have more chronic sinusitis; no age-adjusted dose exists.

  • Baseline state: No lab threshold sets the dose. The ongoing trial enrolls chronic sinusitis after sinus surgery, not a biomarker cutoff.

  • Other conditions: Immune suppression and abnormal valves are reasons to avoid live cells, not to adjust the dose. An antibiotic course for acute bacterial sinusitis will inactivate a live dose.

Discontinuation & Cycling

  • Course length: Label use and the self-experiments are short and symptom-triggered, not lifelong daily dosing. The irrigation trial tests 14 days.

  • Withdrawal: No withdrawal syndrome is described for stopping.

  • Taper: No taper is described. Applications simply stop.

  • Cycling: Scheduled on-off cycling has not been tested. Continuous daily use is not known to hold an effect once symptoms have settled.

Sourcing and Quality

  • Live refrigerated powder: Look for a named strain (proBio65), a CFU count dated at manufacture, a refrigeration statement, and a near expiration date. Potency falls after the bottle is opened; sellers suggest a few months.

  • The studied strain is not the retail strain: Mouse protection used a culture-collection strain. The retail powder is a kimchi strain. An effect in one does not prove the other.

  • Kimchi: Only live, unpasteurized kimchi could contain this species, and many jars do not. Species is not printed on food labels, so a jar is an unstandardized source.

  • Brand and testing: Lanto Health sells the powder made in South Korea under good manufacturing practice and states in-house checks. Public third-party certificates are limited. It is a dietary supplement, not an approved drug. The seller markets it for sinus support.

  • Meat starters are a poor nasal source: Some sausage cultures contain this species plus other organisms, including staphylococci, and are not made for the nose.

Practical Considerations

  • Time to effect: Self-reports describe changes over days to about two weeks. No controlled time course exists, so that window is anecdotal.

  • Common pitfalls: A pasteurized or warm-stored product, an antibacterial rinse on the same days, reading one mouse experiment as a human result, and assuming every kimchi contains the species.

  • Regulatory status: In the United States it is a dietary supplement. The label states it is not intended to diagnose, treat, cure, or prevent any disease. Nasal use of an oral-supplement powder is not an approved drug route.

  • Access: It is a refrigerated specialty product from few sellers, not an ordinary pharmacy item. Cold-chain shipping limits availability. Cost is modest next to sinus surgery, which insurers cover and this powder is not. That payment gap structurally biases research funding and guideline formation.

Interaction with Foundational Habits

  • Sleep: No direct effect on sleep is established. Nasal obstruction itself fragments sleep, so any easing of blockage would be an indirect benefit. Nothing about this organism argues for a stimulating add-on at night.

  • Nutrition: The direction is indirect. This is a fermented-food bacterium, and live fermented vegetables are how some people encounter it, but food content is unreliable as a dose. Antibacterial mouthwashes can inactivate an oral rinse. No specific diet is required.

  • Exercise: No blunting or strengthening of training is reported. Hard efforts force mouth breathing, which bypasses the nose; easier efforts that stay nasal keep air moving over a topical dose. No workout-timing rule is established.

  • Stress management: No effect on cortisol or the stress response is known. Direction: none established. Chronic stress and short sleep track with worse sinus symptoms through inflammation, which is indirect and not specific to this organism.

Monitoring Protocol & Defining Success

Before a nasal or oral course, the useful baseline is a symptom score, not a blood panel. For sinus use, that is a 22-item Sino-Nasal Outcome Test (SNOT-22, a 0–110 symptom score; higher is worse) plus a short note of congestion, pressure, smell, and post-nasal drip. No blood test has a defined role in otherwise healthy adults. Possible immune suppression or a valve problem needs settling first, because the risk in view is invasive infection, not a shifted lab value.

Repeat the same score at about 2 weeks and at 4–6 weeks, then only if symptoms return. A drop of about 9 points is a widely cited noticeable change after surgery; about 12 points has been proposed for medicine-treated sinusitis. Neither number was derived for this organism. Track the person’s own baseline. New fever or spreading facial pain is a safety signal, not success.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
SNOT-22 No organism-specific target. Track change from the person’s own baseline; a drop of at least 9 points is a widely cited noticeable change Sinus symptom burden Scale is 0–110. Healthy volunteers in the original validation averaged about 9. Use the same time of day each time. Not a fasting test.
Body temperature No functional target. Track the person’s own baseline and any new fever Early flag for invasive infection Conventional fever cutoff is 38.0 °C. Any new fever is a reason to stop, not a dosing goal.
Nasal comfort after application No numeric target. Record new burning, bleeding, or sneezing Local irritation from a topical dose Note symptoms within an hour of use.
  • Nasal airflow through both nostrils at rest
  • Facial pressure and post-nasal drip
  • Sense of smell
  • Sleep continuity, as an indirect marker of obstruction
  • Days that an antibiotic or a steroid spray was used, as a practical flare count

Emerging Research

  • Nasal irrigation trial: A double-blind phase 2 study (NCT05427695) is testing whether Lactobacillus sakei proBio65 irrigation twice daily for 14 days beats saline in about 60 adults with chronic sinusitis after sinus surgery. It is recruiting. Primary completion is estimated for March 2028. No results are posted.

  • A class-level null would weaken the case: Abbas et al., 2025 pooled other strains, not this species, and did not find a significant symptom-score benefit. A similar result for proBio65 would cut against expecting a sinus-symptom effect.

  • Strain may matter more than the species name: Martens et al., 2021 found that nose isolate Latilactobacillus sakei AMBR8 did not restore the lining seal, unlike another lactobacillus. The wrong strain could miss an effect or show this species is a poor choice.

  • The mouse result is still unreplicated in people: Protection from Corynebacterium tuberculostearicum rests on one mouse experiment (Abreu et al., 2012). A negative human trial would leave it as an animal finding. A positive one would be the first symptom test of this species in the nose.

Conclusion

Lactobacillus sakei is a food bacterium with a plausible place in the sinus community and almost no human evidence that nasal application changes symptoms. People with long-running sinus inflammation tend to have fewer lactic-acid bacteria and a thinner community. In mice, one strain limited injury from a troublesome bacterium. A later lab study found a nose isolate of this species did not reseal a leaky lining, while a different lactobacillus did. Self-experiments and a commercial powder fill that gap.

Oral use is a different question. Skin scores in children and adolescents are the strongest human signal, and cheek elasticity improved in one trial of healthy women. One exploratory trial found a modest gain in knee pain and function. Body-fat results disagree by strain, though visceral fat fell in one. Oral trials found mild adverse events at rates like placebo. Bloodstream or heart-valve infection is rare for other lactobacilli when immunity is very weak or a valve is abnormal. One case report names this species in a joint infection, not in the bloodstream. Nasal irritation appears only in anecdotes.

The group behind the mouse result later patented this bacterium for sinusitis. The studied powder is sold for sinus support, and company authors developed the knee (LISCure), cheek (Kaneka), and fat-mass (CJ CheilJedang, Dongwha) strains. Insurers pay for surgery, not this supplement, which tilts what gets studied. For a risk-aware adult, the sinus case is a mechanism plus a mouse result. Uncertainty sits on symptoms, not on a settled verdict.

Top - Benefits - Risks - Protocol